Antiviral treatment of COVID-19
Keywords:
Antiviral treatment, COVID-19Abstract
Background: The literature on antiviral treatments for COVID-19 reflects a rapidly evolving field, characterized by a diversity of therapeutic strategies and ongoing clinical investigations. The collaborative efforts of various institutions have been pivotal in identifying effective treatment options, as evidenced by the RECOVERY trial's findings on dexamethasone and remdesivir's efficacy (Sarkar et al., 2020). The urgency for effective treatments is underscored by the ongoing transmission of the virus and the emergence of new variants, necessitating a comprehensive evaluation of available antiviral agents. Literature Review: Favipiravir has emerged as a significant candidate for treating mild to moderate COVID-19 cases, with systematic reviews and meta-analyses indicating its clinical efficacy (Hassanipour et al., 2021). The comparative analysis of favipiravir and remdesivir highlights their mechanisms of action, reinforcing the need for continued exploration of these and other antiviral options (Andrei Negru et al., 2022). Furthermore, molnupiravir has gained attention for its promising pharmacokinetics and clinical trial results, demonstrating its potential in the antiviral arsenal against COVID-19 (Khiali et al., 2022). The landscape of antiviral therapies is further enriched by a comprehensive review of small-molecular therapeutics, emphasizing the need for novel strategies to address the challenges posed by emerging variants (Zhong et al., 2022). The repurposing of established drugs with known safety profiles remains a critical area of focus, as highlighted by the analysis of various antiviral agents, including remdesivir and favipiravir (Sahin et al., 2022).. Conclusion: In conclusion, the body of literature reflects significant advancements in the antiviral treatment of COVID-19 while highlighting the complexities and challenges that remain. The continuous evaluation and adaptation of therapeutic strategies are essential to effectively combat the evolving landscape of COVID-19 and its associated variants.
References
Sarkar, C., Mondal, M., Torequl Islam, M., Martorell, M., Oana Docea, A., Maroyi, A., Sharifi-Rad, J., & Calina, D., 2020. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. ncbi.nlm.nih.gov
Zhang, Z. L., Zhong, H., Liu, Y. X., Le, K. J., Cui, M., Yu, Y. T., Gu, Z. C., Gao, Y., & Lin, H. W., 2020. Current therapeutic options for coronavirus disease 2019 (COVID-19)—lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol. ncbi.nlm.nih.gov
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R., 2021. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. ncbi.nlm.nih.gov
Andrei Negru, P., Radu, A. F., Mihai Vesa, C., Behl, T., M. Abdel-Daim, M., Cristina Nechifor, A., Endres, L., Stoicescu, M., Pasca, B., Mirela Tit, D., & Gabriela Bungau, S., 2022. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. ncbi.nlm.nih.gov
Khiali, S., Khani, E., B Rouy, S., & Entezari-Maleki, T., 2022. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. ncbi.nlm.nih.gov
Zhong, L., Zhao, Z., Peng, X., Zou, J., & Yang, S., 2022. Recent advances in small-molecular therapeutics for COVID-19. ncbi.nlm.nih.gov
Sahin, G., Akbal-Dagistan, O., Culha, M., Erturk, A., Sena Basarir, N., Sancar, S., & Yildiz-Pekoz, A., 2022. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. ncbi.nlm.nih.gov
Banerjee, S., Banerjee, D., Singh, A., Kumar, S., Pooja, D., Ram, V., Kulhari, H., & Anand Saharan, V., 2023. A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. ncbi.nlm.nih.gov
Yasir, M., Reddy Lankala, C., Kalyankar, P., Ishak, A., Mekhail, M., Sestacovschi, C., & Kima, E., 2023. An Updated Systematic Review on Remdesivir’s Safety and Efficacy in Patients Afflicted With COVID-19. ncbi.nlm.nih.gov
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Andina, Sugiarto, Pamungkas (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
